drugset / Trial / NCT00022386

Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer

NCT00022386

Supportive care

Summary

RATIONALE: Epoetin alfa may stimulate red blood cell production to treat patients who have anemia following chemotherapy. PURPOSE: Phase IV trial to study the effectiveness of epoetin alfa in treating chemotherapy-related anemia in women who have stage I, stage II, or stage III breast cancer.

Timeline

Start
Primary completion
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic Subcutaneous

Indications